MAPT and Alzheimer disease: Recent research suggests that heterozygosity for the KLOTHO-VS (KL-VS) haplotype may be associated with a reduced burden of key AD biomarkers, such as cerebrospinal fluid (CSF) amyloid-β (Aβ) 42, total tau (T-tau), and phosphorylated tau (P-tau).